Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|15|14|1263-1272

ISSN： 1389-4501

Source： Current Drug Targets, Vol.15, Iss.14, 2014-01, pp. : 1263-1272

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer

By  

Current Cancer Drug Targets, Vol. 12, Iss. 3, 2012-03 ,pp. : 237-246

Bentham Science Publishers

Access to resources Recommend Favorite

Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer

By  

Current Cancer Drug Targets, Vol. 15, Iss. 9, 2015-11 ,pp. : 792-802

Bentham Science Publishers

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer

By Dancey Janet E.  

Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. : 1125-1138

Adis International

Access to resources Recommend Favorite

Thymidylate synthase inhibitors for non-small cell lung cancer

By Galvani Elena   Peters Godefridus J   Giovannetti Elisa  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1343-1356

Informa Healthcare

Access to resources Recommend Favorite

Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 17, Iss. 6, 2016-05 ,pp. : 739-745

Bentham Science Publishers

Access to resources Recommend Favorite